Is CRIS or BOLT more profitable?

Curis has a net margin of -80.29% compared to Bolt Biotherapeutics' net margin of -455.15%. Curis' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% N/A -181.57% Bolt Biotherapeutics -455.15% -100.89% -48.23%

Is BOLT or AMGN more profitable?

Amgen has a net margin of 20.96% compared to Bolt Biotherapeutics' net margin of -455.15%. Amgen's return on equity of 137.41% beat Bolt Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Bolt Biotherapeutics -455.15% -100.89% -48.23% Amgen 20.96% 137.41% 13.28%

Bolt Biotherapeutics (BOLT) Competitors

$3.99 0.00 (0.00%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$3.92 -0.07 (-1.85%)

As of 07/31/2026 06:27 PM Eastern

Compare

BOLT vs. CRIS, AMGN, GILD, VRTX, and REGN

Should you buy Bolt Biotherapeutics stock or one of its competitors? MarketBeat compares Bolt Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bolt Biotherapeutics include Curis (CRIS), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "biotechnology" industry.

How does Bolt Biotherapeutics compare to Curis?

Curis (NASDAQ:CRIS) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Curis has a beta of 3.13, meaning that its stock price is 213% more volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

Curis currently has a consensus price target of $43.00, indicating a potential upside of 756.57%. Bolt Biotherapeutics has a consensus price target of $34.67, indicating a potential upside of 768.84%. Given Bolt Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Curis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

30.0% of Curis shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 5.8% of Curis shares are held by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Curis has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	1.04	-$7.58M	-$23.80	N/A
Bolt Biotherapeutics	$7.70M	0.99	-$33.38M	-$16.33	N/A

In the previous week, Curis had 10 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 10 mentions for Curis and 0 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 0.00 beat Curis' score of -0.25 indicating that Bolt Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Curis	Neutral
Bolt Biotherapeutics	Neutral

Curis has a net margin of -80.29% compared to Bolt Biotherapeutics' net margin of -455.15%. Curis' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-181.57%
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%

Summary

Curis and Bolt Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Amgen?

Bolt Biotherapeutics (NASDAQ:BOLT) and Amgen (NASDAQ:AMGN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

Amgen has a net margin of 20.96% compared to Bolt Biotherapeutics' net margin of -455.15%. Amgen's return on equity of 137.41% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%
Amgen	20.96%	137.41%	13.28%

Bolt Biotherapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Amgen has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

Bolt Biotherapeutics currently has a consensus target price of $34.67, suggesting a potential upside of 768.84%. Amgen has a consensus target price of $357.00, suggesting a potential downside of 7.31%. Given Bolt Biotherapeutics' higher possible upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Amgen	2 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.43

Amgen has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	0.99	-$33.38M	-$16.33	N/A
Amgen	$36.75B	5.66	$7.71B	$14.37	26.80

In the previous week, Amgen had 55 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 55 mentions for Amgen and 0 mentions for Bolt Biotherapeutics. Amgen's average media sentiment score of 1.05 beat Bolt Biotherapeutics' score of 0.00 indicating that Amgen is being referred to more favorably in the news media.

Company	Overall Sentiment
Bolt Biotherapeutics	Neutral
Amgen	Positive

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 0.9% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Amgen beats Bolt Biotherapeutics on 13 of the 17 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Bolt Biotherapeutics (NASDAQ:BOLT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Gilead Sciences has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

In the previous week, Gilead Sciences had 46 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 46 mentions for Gilead Sciences and 0 mentions for Bolt Biotherapeutics. Gilead Sciences' average media sentiment score of 0.92 beat Bolt Biotherapeutics' score of 0.00 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Gilead Sciences	Positive
Bolt Biotherapeutics	Neutral

Gilead Sciences has a net margin of 30.99% compared to Bolt Biotherapeutics' net margin of -455.15%. Gilead Sciences' return on equity of 48.19% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	30.99%	48.19%	18.28%
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Gilead Sciences has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	5.49	$8.51B	$7.34	17.74
Bolt Biotherapeutics	$7.70M	0.99	-$33.38M	-$16.33	N/A

Gilead Sciences currently has a consensus target price of $157.93, indicating a potential upside of 21.29%. Bolt Biotherapeutics has a consensus target price of $34.67, indicating a potential upside of 768.84%. Given Bolt Biotherapeutics' higher possible upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Gilead Sciences beats Bolt Biotherapeutics on 12 of the 16 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Bolt Biotherapeutics (NASDAQ:BOLT) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Vertex Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

In the previous week, Vertex Pharmaceuticals had 42 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 42 mentions for Vertex Pharmaceuticals and 0 mentions for Bolt Biotherapeutics. Vertex Pharmaceuticals' average media sentiment score of 1.15 beat Bolt Biotherapeutics' score of 0.00 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Vertex Pharmaceuticals	Positive
Bolt Biotherapeutics	Neutral

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vertex Pharmaceuticals currently has a consensus target price of $559.61, indicating a potential upside of 17.29%. Bolt Biotherapeutics has a consensus target price of $34.67, indicating a potential upside of 768.84%. Given Bolt Biotherapeutics' higher probable upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.88
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Vertex Pharmaceuticals has a net margin of 35.51% compared to Bolt Biotherapeutics' net margin of -455.15%. Vertex Pharmaceuticals' return on equity of 23.86% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%

Vertex Pharmaceuticals has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	10.09	$3.95B	$16.86	28.30
Bolt Biotherapeutics	$7.70M	0.99	-$33.38M	-$16.33	N/A

Summary

Vertex Pharmaceuticals beats Bolt Biotherapeutics on 13 of the 16 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Bolt Biotherapeutics (NASDAQ:BOLT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Regeneron Pharmaceuticals has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.62	$4.50B	$40.46	18.85
Bolt Biotherapeutics	$7.70M	0.99	-$33.38M	-$16.33	N/A

In the previous week, Regeneron Pharmaceuticals had 95 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 95 mentions for Regeneron Pharmaceuticals and 0 mentions for Bolt Biotherapeutics. Regeneron Pharmaceuticals' average media sentiment score of 0.69 beat Bolt Biotherapeutics' score of 0.00 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Regeneron Pharmaceuticals	Positive
Bolt Biotherapeutics	Neutral

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals presently has a consensus target price of $794.83, suggesting a potential upside of 4.22%. Bolt Biotherapeutics has a consensus target price of $34.67, suggesting a potential upside of 768.84%. Given Bolt Biotherapeutics' higher probable upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.70
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Bolt Biotherapeutics' net margin of -455.15%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Bolt Biotherapeutics	-455.15%	-100.89%	-48.23%

Regeneron Pharmaceuticals has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Summary

Regeneron Pharmaceuticals beats Bolt Biotherapeutics on 13 of the 17 factors compared between the two stocks.

Get Bolt Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BOLT vs. The Competition

Export

Metric	Bolt Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.66M	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-0.24	7.38	282.30	24.66
Price / Sales	0.99	1,182.44	561.34	76.65
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	0.29	16.96	10.98	6.07
Net Income	-$33.38M	-$12.56M	$3.49B	$347.99M
7 Day Performance	0.50%	-1.76%	-0.60%	-0.44%
1 Month Performance	-1.48%	-8.38%	-5.20%	-4.81%
1 Year Performance	-27.85%	48.40%	62.01%	18.61%

Bolt Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BOLT Bolt Biotherapeutics	2.9556 of 5 stars	$3.99 flat	$34.67 +768.8%	-27.8%	$7.66M	$7.70M	N/A	90	Positive News
CRIS Curis	2.8262 of 5 stars	$4.83 +3.0%	$43.00 +790.3%	-84.6%	$9.14M	$9.44M	N/A	60	Upcoming Earnings
AMGN Amgen	3.9379 of 5 stars	$393.10 +4.5%	$356.62 -9.3%	+29.7%	$203.07B	$36.75B	27.36	31,500	Trending News Upcoming Earnings Dividend Announcement
GILD Gilead Sciences	4.9353 of 5 stars	$134.32 +2.9%	$158.30 +17.9%	+15.0%	$162.05B	$29.44B	18.30	17,000	Trending News Upcoming Earnings Analyst Downgrade
VRTX Vertex Pharmaceuticals	4.4748 of 5 stars	$490.39 +2.4%	$559.61 +14.1%	+3.2%	$121.57B	$12.00B	29.09	6,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BOLT) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bolt Biotherapeutics (BOLT) Competitors

BOLT vs. CRIS, AMGN, GILD, VRTX, and REGN

How does Bolt Biotherapeutics compare to Curis?

Summary

How does Bolt Biotherapeutics compare to Amgen?

Summary

How does Bolt Biotherapeutics compare to Gilead Sciences?

Summary

How does Bolt Biotherapeutics compare to Vertex Pharmaceuticals?

Summary

How does Bolt Biotherapeutics compare to Regeneron Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT vs. The Competition

Bolt Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bolt Biotherapeutics (BOLT) Competitors

BOLT vs. CRIS, AMGN, GILD, VRTX, and REGN

How does Bolt Biotherapeutics compare to Curis?

Which has more volatility & risk, CRIS or BOLT?

Do analysts prefer CRIS or BOLT?

Do insiders and institutionals hold more shares of CRIS or BOLT?

Which has preferable valuation & earnings, CRIS or BOLT?

Does the media favor CRIS or BOLT?

Is CRIS or BOLT more profitable?

Summary

How does Bolt Biotherapeutics compare to Amgen?

Is BOLT or AMGN more profitable?

Which has more volatility and risk, BOLT or AMGN?

Do analysts recommend BOLT or AMGN?

Which has better earnings & valuation, BOLT or AMGN?

Does the media favor BOLT or AMGN?

Do insiders and institutionals hold more shares of BOLT or AMGN?

Summary

How does Bolt Biotherapeutics compare to Gilead Sciences?

Which has more risk & volatility, GILD or BOLT?

Does the media refer more to GILD or BOLT?

Is GILD or BOLT more profitable?

Do insiders & institutionals hold more shares of GILD or BOLT?

Which has better valuation & earnings, GILD or BOLT?

Do analysts recommend GILD or BOLT?

Summary

How does Bolt Biotherapeutics compare to Vertex Pharmaceuticals?

Which has more volatility and risk, VRTX or BOLT?

Does the media refer more to VRTX or BOLT?

Do insiders and institutionals believe in VRTX or BOLT?

Do analysts recommend VRTX or BOLT?

Is VRTX or BOLT more profitable?

Which has stronger earnings & valuation, VRTX or BOLT?

Summary

How does Bolt Biotherapeutics compare to Regeneron Pharmaceuticals?

Which has higher earnings & valuation, REGN or BOLT?

Does the media prefer REGN or BOLT?

Do insiders & institutionals hold more shares of REGN or BOLT?

Do analysts recommend REGN or BOLT?

Is REGN or BOLT more profitable?

Which has more volatility & risk, REGN or BOLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT vs. The Competition

Bolt Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools